Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
Open Access
- 1 January 2011
- journal article
- Published by Taylor & Francis Ltd in ClinicoEconomics and Outcomes Research
- Vol. 3, 9-14
- https://doi.org/10.2147/ceor.s16061
Abstract
Purpose: To assess change in hospitalization and cost of care from 6 months pre- to 6 months post-initiation on any depot antipsychotic among schizophrenia patients. Patients and methods: Using a large United States commercial claims and encounters database, patients younger than 65 years diagnosed with schizophrenia were identified. Patients initiated on a depot antipsychotic were studied in a mirror-image design to assess change in hospitalization rates, mean duration hospitalized, and hospitalization cost. McNemar’s test and paired t-tests compared the proportions of patients hospitalized and the mean duration. Paired t-test and bootstrapping methods compared costs. Results: In these patients (n = 147), psychiatric hospitalizations declined from 49.7% pre-initiation to 22.4% post-initiation (P < 0.001), and the mean hospitalized duration for psychiatric purposes numerically declined from 7.3 to 4.7 days (P = 0.05). Total health care costs declined from $11,111 to $7884 (P < 0.05) driven by reduction in costs for psychiatric hospitalizations from $5384 to $2538 (P < 0.05). Conclusion: Initiation of depot antipsychotic therapy appeared to be associated with a decline in hospitalization rates and costs. Current findings suggest that treatment with depot antipsychotics may be a cost-effective option for a subgroup of patients with schizophrenia who are at high risk of nonadherence with their oral antipsychotic medication regimen.Keywords
This publication has 19 references indexed in Scilit:
- First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studiesThe British Journal of Psychiatry, 2009
- Impact of risperidone long acting injection on resource utilization in psychiatric secondary careJournal of Psychopharmacology, 2008
- Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder.British Journal of Psychology, 2007
- Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotics or Oral Antipsychotics for SchizophreniaPsychiatric Services, 2007
- Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychoticNeuropsychiatric Disease and Treatment, 2007
- Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Medicine, 2005
- Compliance With Medication Regimens for Mental and Physical DisordersPsychiatric Services, 1998
- Guidelines for depot antipsychotic treatment in schizophreniaEuropean Neuropsychopharmacology, 1998
- Depot Antipsychotic DrugsDrugs, 1994
- A brief history of depot neuroleptics.1984